EMD527040
Modify Date: 2024-01-09 17:05:38
EMD527040 structure
|
Common Name | EMD527040 | ||
|---|---|---|---|---|
| CAS Number | 851333-14-7 | Molecular Weight | 587.49 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H32Cl2N4O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EMD527040EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research[1]. |
| Name | EMD527040 |
|---|
| Description | EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research[1]. |
|---|---|
| Related Catalog | |
| Target |
αvβ6:6 nM (IC50) |
| In Vitro | EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC5050)[1]. EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC50 of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins[1]. |
| In Vivo | EMD527040 (intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4)-/- mice[1]. Animal Model: Male adult Wistar rats Dosage: 20-60 mg/kg Administration: Intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation) Result: Ameliorated fibrosis progression in rodents with biliary fibrosis. |
| References |
| Molecular Formula | C29H32Cl2N4O5 |
|---|---|
| Molecular Weight | 587.49 |